Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Apathy is one of the most common effects of Alzheimer's disease (AD).

The loss of interest and motivation in daily life experienced with Alzheimer's disease was successfully decreased in patients in a recent trial.

"Apathy is one of the most common effects of Alzheimer's disease (AD).  It decreases these patients' quality of life, it has been shown to worsen their ability to carry out activities of daily living, and it is often a key contributing factor to being institutionalized," says Dr. Krista Lanctôt, primary author of a new study and neuropsychopharmacologist at Sunnybrook Health Sciences Centre.  "If we can treat the apathy, then we may be able to prevent this downward spiral and really, change the course of illness for someone with Alzheimer's disease."

Study participants randomized to receive treatment were treated for six weeks with the drug methylphenidate - a treatment that the Sunnybrook team had previously suggested might improve apathy based on neuroimaging findings and pilot data.

Story continues below advertisement

The participants showed a significant reduction in apathy symptoms, as well as some improvements in "global cognition" which includes attention, memory, language, learning, reasoning, problem solving and decision making.

"This treatment is promising as it appears to be effective and with minor side effects," says Dr. Nathan Herrmann, head of Geriatric Psychiatry at Sunnybrook and Professor of Psychiatry at University of Toronto.  "We require further research."

Preliminary data were presented at the Alzheimer's Association International Conference in July 2012, and a manuscript is currently in press with The Journal of Clinical Psychiatry.

An army of dementia researchers are increasingly working at discovering ways to prevent, cure, and treat symptoms. This research work falls under the latter, which is essentially working to modify what the illness looks and acts like. With the failure of recent trials, this is an encouraging success.

"This research aims to understand and treat effects of the disease for those who are diagnosed with it," says Lanctôt, also a Professor of Psychiatry at the University of Toronto.  "So that one may have Alzheimer's disease but maximize quality of life for a longer period of time."

In addition to the effects on the patient's quality of life and functional impairment, apathy in AD is also associated with greater caregiver burden and higher costs of care.  AD is the major neurodegenerative disease of aging, affecting an estimated 481 thousand persons in Canada in 2008 and increasing to 1.1 million by 2038.

Funded by the National Institute on Aging, this study was a multicenter, randomized, placebo-controlled, double blind trial.  The research was a collaborative effort by investigators from Johns Hopkins School of Medicine, Sunnybrook, John Hopkins Bloomberg School of Public Health, Medical University of South Carolina, and the Ralph H. Johnson VA Medical Center. We are grateful to the patients and families who participated in this research.

Story continues below advertisement

This content was produced by The Globe and Mail's advertising department, in consultation with Sunnybrook. The Globe's editorial department was not involved in its creation.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies